The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation

David E Geller, Kenneth C Kesser, David E Geller, Kenneth C Kesser

Abstract

Background: Inhaled alpha1-antitrypsin (AAT) is being developed for treatment of cystic fibrosis to protect the lungs from excessive free elastase. High drug costs mandate a very efficient aerosol system to deliver a high payload to the airways. The I-neb Adaptive Aerosol Delivery (AAD) System is a portable, electronic, vibrating mesh nebulizer that delivers aerosol only during inhalation. It can be operated in conventional tidal breathing mode (TBM) or in target inhalation mode (TIM) that guides the patient to inhale deeply and slowly. The purposes of this in vitro study were to determine aerosol characteristics, device efficiency, and delivery time of AAT using the I-neb AAD System with TBM and TIM.

Methods: We studied the I-neb AAD System in TBM and TIM (inspiratory time 6 or 9 sec) using a breath simulator. The loaded dose was 0.5 mL AAT (50 mg/mL). Nebulized drug captured on an inspiratory filter was reported as emitted dose. Particle size was measured by laser diffraction. Predicted lung doses were calculated based on the results of a prior scintigraphy study of the I-neb AAD System.

Results: Particle size (VMD) for TBM and TIM was similar (4.4-4.8 microm). The emitted doses were very high and similar between modes (82-90% of loaded dose). Predicted lung dose of AAT (percent of loaded dose) and delivery times were: TBM 56.6% in 7.5 min; TIM-6 59.9% in 4.4 min; and TIM-9 64.5% in 2.5 min.

Conclusions: The I-neb AAD System enhanced AAT delivery by inhalation-only aerosol generation and a low-residual dose. Predicted lung dose was high for both TBM and TIM, but longer inspiratory times with TIM reduced the administration time to one-third that of tidal breathing. We conclude that slow, deep, controlled inspirations using the I-neb AAD System is an efficient method to deliver AAT.

Figures

FIG. 1.
FIG. 1.
The I-neb Adaptive Aerosol Delivery (AAD) System.
FIG. 2.
FIG. 2.
Breath patterns for Tidal Breathing Mode (TBM) and Targeted Inhalation Mode (TIM) with 6- and 9-sec inspiratory times.

References

    1. Chmiel JF. Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007;28:331–346.
    1. Griese M. Kappler M. Gaggar A. Hartl D. Inhibition of proteases in cystic fibrosis lung disease. Eur Respir J. 2008;32:783–795.
    1. Hubbard RC. Crystal RG. Strategies for aerosol therapy of alpha1-antitrypsin deficiency by the aerosol route. Lung Suppl. 1990;168:565–578.
    1. McElvaney NG. Hubbard RC. Birrer P. Chernick MS. Caplan DB. Frank MM. Crystal RG. Aerosol α1-anti-trypsin treatment for cystic fibrosis. Lancet. 1991;337:392–394.
    1. Berger M. Konstan MW. Hilliard JB. Aerosolized prolastin (α1-protease inhibitor) in CF. Pediatr Pulmonol. 1995;20:421.
    1. Sawicki GS. Sellers DE. Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cystic Fibros. 2009;8:91–96.
    1. Brand P. Friemel I. Meyer T. Schulz H. Heyder J. Häussinger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci. 2000;89:724–731.
    1. Brand P. Meyer T. Häussermann S. Schulte M. Scheuch G. Bernhard T. Sommerauer B. Weber N. Griese M. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med. 2005;18:45–54.
    1. Nikander K. Denyer J. Adaptive aerosol delivery (AAD) technology. In: Rathbone MJ, editor. Modified Release Drug Delivery Technology. 2nd. Informa Healthcare USA, Inc.; New York, NY: 2008. pp. 603–612.
    1. Nikander K. Prince IR. Coughlin SR. Warren S. Taylor G. Mode of breathing—tidal or slow, deep—through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA. Proceedings of Drug Delivery to the Lungs; Edinburgh; Scotland. 2006. pp. 206–209.
    1. Laube BL. Jashnani R. Dalby RN. Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis. Chest. 2000;118:1069–1076.
    1. Bennett WD. Controlled inhalation of aerosolized therapeutics. Expert Opin Drug Deliv. 2005;2:763–767.
    1. CSL Behring: Technical Operations memo: effect of nebulization on Zemaira specific activity. CSL Behring; King of Prussia, PA: 2007.
    1. Martin SL. Downey D. Bilton D. Keogan MT. Edgar J. Elborn JS. Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006;41:177–183.
    1. Brand P. Beckmann H. Enriquez MM. Meyer T. Müllinger B. Sommerer K. Weber N. Weuthen T. Scheuch G. Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22:263–267.
    1. Köhler E. Sollich V. Schuster-Wonka R. Jorch G. Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med. 2005;18:386–395.
    1. Griese M. Latzin P. Kappler M. Weckerle K. Heinzlmaier T. Bernhardt T. Hartl D. α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29:240–250.
    1. Brand P. Schulte M. Wencker M. Herpich CH. Klein G. Hanna K. Meyer T. Lung deposition of inhaled α1-proteinase inhibitor in CF and α1-antitrypsin deficiency. Eur Respir J. 2009;34:354–360.
    1. Denyer J. Black A. Nikander K. Dyche T. Prince I. Domiciliary experience of the target inhalation mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S45–S54.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera